|Day Low/High||7.99 / 8.68|
|52 Wk Low/High||7.61 / 19.99|
The Dublin firm on Nov. 6 unveiled third-quarter numbers that topped analysts' estimates and raised its full-year net sales outlook and the lower end of its 2017 adjusted Ebitda guidance.
BioCryst's Hereditary angioedema drug-trial results not compelling.
The number of new 12-month highs has climbed to 240.
The euphoria has calmed down, and if stocks can consolidate, we will have some better entry points.
Robert Ingram sits on four public company boards and is a director at three private companies, which governance experts view as cause for concern.
U.S. stocks picked up where they left off last week, extending a sharp selloff on Monday on worries over oil and disappointing earnings.
Market players are adding long exposure as the market runs away from them.